Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00828776

Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure (heparin)

Clinical Trial of Pharmacodynamic Effects and Non-Clinical Inferiority of the Drug Heparin Sodium Produced by the Laboratory Cristália When Compared With the Product Liquemine of Roche Laboratory in Patients With Chronic Renal Failure

Sponsor: Azidus Brasil

Conditions Chronic Renal Failure

Interventions Heparin sodic - Cristália heparin - Liquemine (Roche)

Updated 4 times since 2017 Last updated: Jan 23, 2009 Started: Sep 30, 2007 Primary completion: Feb 29, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00828776, this PHASE2/PHASE3 trial focuses on Chronic Renal Failure and remains completed. Sponsored by Azidus Brasil, it has been updated 4 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Azidus Brasil

Data source: Azidus Brasil

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Valinhos, Brazil